ENGLEWOOD, Colo., April 6, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has been ranked 191 out of 500 on The Financial Times fourth annual list of The Americas' Fastest Growing Companies 2023.
"Zynex has consistently grown revenue and profitability over the last several years and we are pleased that our performance has been recognized alongside other innovative organizations," said Thomas Sandgaard, CEO and founder of Zynex. "The Company grew revenue by 308% and achieved a compound annual growth rate (CAGR) of 60% between 2018 and 2021, when the data for the rankings was collected. Additionally, we are pleased to be one of twenty-four publicly traded Healthcare & Life Sciences companies recognized in this high growth category."
The full list is available at: The Americas' Fastest Growing Companies 2023
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com
Contact: Zynex, Inc. (800) 495-6670
Investor Relations Contact:
Gilmartin Group
Investor Relations Counsel
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.16 |
Daily Volume: | 341,666 |
Market Cap: | US$68.800M |
December 12, 2024 December 05, 2024 October 24, 2024 September 04, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load